Christian Manegold

Ontario Institute for Cancer Research — Canada

Medicine · Health Sciences

46h-index21.7kcitations157works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(102), Lung Cancer Research Studies(45), Lung Cancer Diagnosis and Treatment(42), Occupational and environmental lung diseases(22), Colorectal Cancer Treatments and Studies(22)

Publications157 total

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy
Journal of Clinical Oncology·2023· 166 cited
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Journal of Clinical Oncology·2023· 265 cited
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Journal of Clinical Oncology·2023· 252 cited
Supplementary Figure 5 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
Supplementary Figure 4 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
sSupplementary Legends for Figures 1-5 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
Supplementary Figure 2 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
Supplementary Figure 4 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
Supplementary Figure 2 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
sSupplementary Legends for Figures 1-5 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
Supplementary Figure 3 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
Supplementary Figure 1 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
Data from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
Supplementary Figure 1 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
Supplementary Figure 3 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
Data from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
Supplementary Figure 5 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
2023Open Access
A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives
Cells·2023· 19 citedOpen Access
Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer
Current Opinion in Oncology·2019· 26 cited
Defining Aggressive Or Early Progressing Nononcogene-Addicted Non-Small-Cell Lung Cancer: A Separate Disease Entity?
Future Oncology·2019· 13 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Giorgio V. Scagliotti(8), U. Gatzemeier(8), Joachim von Pawel(7), Filippo de Marinis(6), Frances A. Shepherd(6), Giuseppe Giaccone(6), Jan P. van Meerbeeck(6), Johan Vansteenkiste(4), David R. Gandara(4), Paolo Paoletti(4), Rafael Rosell(4), Vera Hirsh(4), J. Blatter(4), Martin Reck(4), Keunchil Park(3), Lorinda Simms(3), Katherine P. Sugarman(3), James J. Rusthoven(3), James T. Symanowski(3), E. Kaukel(3)